A Study of MACI in Patients Aged 10 to 17 Years With Symptomatic Chondral or Osteochondral Defects of the Knee

Who May Qualify: - Symptomatic cartilage or osteochondral defects - One or more International Cartilage Repair Society (ICRS) Grade III or IV chondral or unsalvageable osteochondral defects located on the femoral condyles and/or trochlea amenable to treatment with the surgical procedure determined at randomization (MACI or microfracture). - At least 1 defect size ≥1.5 cm2 on the femoral condyles and/or the trochlea; defects include OCD lesions with a bone lesion depth of ≤6 mm and does not require a bone graft. - Stable target knee (i.e., anterior and posterior cruciate ligaments should be free of laxity as well as stable and intact). Ligament repair or reconstruction procedures are allowed prior to screening arthroscopy. - Intact meniscus or partial meniscus (at least 50% of functional meniscus remaining) in the target knee. Who Should NOT Join This Trial: - Any surgery on the target knee joint within 6 months prior to Screening (not including diagnostic arthroscopy) - ICRS Grade III or IV chondral or unsalvageable osteochondral defects located on the patella or tibia or any lesion that is bipolar to the index lesion - Concomitant inflammatory disease or other conditions that affects the joints (eg, rheumatoid arthritis, metabolic bone disease, psoriasis, symptomatic chondrocalcinosis) - Known history of septic arthritis in the index knee joint - Known history of hypersensitivity to gentamicin, other aminoglycosides, or products of porcine or bovine origin - Females who are pregnant or lactating Always talk to your doctor about whether this trial is right for you.